Literature DB >> 25118195

Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.

Kyu-Sup Cho1, Ethan Soudry2, Alkis J Psaltis2, Kari C Nadeau3, Sean A McGhee3, Jayakar V Nayak2, Peter H Hwang4.   

Abstract

OBJECTIVE: This study aimed to assess sinonasal outcomes in patients with aspirin exacerbated respiratory disease (AERD) undergoing aspirin desensitization following endoscopic sinus surgery (ESS). STUDY
DESIGN: Case series with chart review.
SETTING: University hospital. SUBJECTS AND METHODS: A retrospective review of sinonasal outcomes was conducted for 30 AERD patients undergoing aspirin desensitization and maintenance therapy following ESS. Sinonasal outcomes were prospectively assessed by the Sinonasal Outcomes Test-22 (SNOT-22) and endoscopic polyp grading system. Data were collected preoperatively, 1 and 4 weeks postsurgery (before desensitization), and 1, 6, 12, 18, 24, and 30 months after aspirin desensitization.
RESULTS: Twenty-eight of 30 patients (93.3%) successfully completed aspirin desensitization, whereas 2 of 30 (6.7%) were unable to complete desensitization due to respiratory intolerance. Of the 21 patients who successfully completed a minimum of 24 weeks of follow-up, 20 (95.2%) patients demonstrated sustained endoscopic and symptomatic improvement for a median follow-up period of 33 months. After surgical treatment but before desensitization, patients experienced significant reductions in SNOT-22 and polyp grade scores. In the first 6 months after aspirin desensitization, patients experienced further significant reductions in SNOT-22 scores, whereas polyp grade remained stable. The improvements in symptom endoscopic scores were preserved throughout the follow-up period after desensitization. No patients required additional sinus surgery. One patient had to discontinue aspirin therapy due to gastrointestinal side effects. No other adverse reactions to aspirin were noted.
CONCLUSION: Aspirin desensitization following ESS appears to be a well-tolerated and effective adjunctive therapy for long-term control of nasal polyposis in patients with AERD. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2014.

Entities:  

Keywords:  aspirin exacerbated respiratory disease; asthma; desensitization; endoscopic sinus surgery; nasal polyps; sinusitis

Mesh:

Substances:

Year:  2014        PMID: 25118195     DOI: 10.1177/0194599814545750

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  20 in total

Review 1.  Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).

Authors:  Ronald A Simon; Kristen M Dazy; Jeremy D Waldram
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

Review 2.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 3.  Update on Aspirin-Exacerbated Respiratory Disease.

Authors:  Katharine M Woessner
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.806

Review 4.  Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.

Authors:  Joshua M Levy; Luke Rudmik; Anju T Peters; Sarah K Wise; Brian W Rotenberg; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-08-02       Impact factor: 3.858

Review 5.  Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis.

Authors:  Zachary M Soler; Rabun Jones; Phong Le; Luke Rudmik; Jose L Mattos; Shaun A Nguyen; Rodney J Schlosser
Journal:  Laryngoscope       Date:  2017-11-22       Impact factor: 3.325

6.  Long-term assessment of aspirin desensitization shows successful bridging with non-aspirin nonsteroidal anti-inflammatory drugs for procedures.

Authors:  Toan Do; Ethan Canty; Puneet Bajaj; Faoud Ishmael; Timothy Craig
Journal:  Allergy Asthma Proc       Date:  2019-09-01       Impact factor: 2.587

7.  Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.

Authors:  V Gudziol; M Michel; C Sonnefeld; D Koschel; T Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-11-09       Impact factor: 2.503

Review 8.  Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future.

Authors:  Joshua L Kennedy; Ashley N Stoner; Larry Borish
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

9.  Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.

Authors:  Sharan J Shah; Waleed M Abuzeid; Anusha Ponduri; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; David Rosenstreich; Denisa Ferastraoaru; Elina Jerschow
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-30       Impact factor: 3.858

Review 10.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.